Guillain-Barré Condition (GBS) is a rare neurological disorder that can cause sudden weakness and tingling in your extremities. Induced by an immune system malfunction, GBS often follows a viral or bacterial infection. This condition can affect individuals of all ages, but its frequency tends to be higher among adults between 50 and 70 years old.

For years, muscular dystrophy (MD) has presented a daunting obstacle to patients and families worldwide. However, recent developments in research offer a sign of hope for the future. Scientists are tirelessly working on groundbreaking treatments that aim to not only treat symptoms but also to halt the progression of this debilitating disease. One

through symptomatic attacks, administration of superior doses of intravenous corticosteroids, for instance methylprednisolone, is the same old therapy,[1] with oral corticosteroids seeming to possess the same efficacy and basic safety profile.[a hundred thirty] Whilst productive in the short-term for relieving symptoms, corticosteroid treatments wi